Brickell Biotech (BBI) Regains Nasdaq Compliance

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI) today announced that it received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that Brickell has regained compliance with the minimum bid price requirement for continued listing on Nasdaq and, accordingly, the scheduled hearing has been canceled and Brickell’s common stock will continue to be listed and traded on Nasdaq.

You May Also Be Interested In

• Kimbell Royalty closes $221.2M mineral rights acquisition
• Lazard Global Total Return fund declares $0.1534 monthly distribution
• Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests